This trial is evaluating whether CUE-101 will improve 6 primary outcomes and 5 secondary outcomes in patients with Carcinoma, Squamous Cell. Measurement will happen over the course of From start of treatment through start of standard of care therapy (estimated to be 2 weeks).
This trial requires 30 total participants across 3 different treatment groups
This trial involves 3 different treatments. CUE-101 is the primary treatment being studied. Participants will be divided into 3 treatment groups. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.
"It is important to be vigilant for the development of carcinoma, squamous cell, as a side effect of lung damage due to radiation or asbestos exposure." - Anonymous Online Contributor
"Carcinomas of all sites are often treated effectively by surgical removal or radiotherapy followed by adjuvant therapy with hormone, antiestrogen, immunotherapy or chemotherapeutics (such as epoetin alfa, carboplatin, and methotrexate). Local or regional treatment of carcinoma, squamous cell, is often the only option available. Prostate cancer in which the primary tumour is squamous cell is treated by radical prostatectomy." - Anonymous Online Contributor
"Carcinoma, squamous cell, cannot be cured. There is no evidence that treatment can prevent reoperation for recurrent cancer. However, long-term survival can be predicted, especially in the presence of negative lymph nodes." - Anonymous Online Contributor
"Carcinoma, squamous cell is the third most common type of malignancy among women aged 0-39 years. Most cases of squamous cell carcinoma are associated with the use of tobacco and alcohol, especially with cigarette use." - Anonymous Online Contributor
"Most people with carcinoma, squamous cell have symptoms over 5 days or more. These symptoms tend to be progressive and can include fever, muscle pains, nausea and vomiting, weight loss, jaundice and blood in the urine or stools. People with carcinoma, squamous cell tend to have a short illness than those with carcinoma, non-squamous cell. There are a group of symptoms that are often present in both carcinoma, squamous cell and carcinoma, non-squamous cell. These are itching, skin rash, fever, fatigue, night sweats, abdominal pain, muscle aches and unexplained weight loss." - Anonymous Online Contributor
"About 9,000 squamous cell carcinoma cases are identified every year in the US. These are usually in males; in men there has been an average increase of 2.5% in incidence since 1970, and in women there has been an average decrease of 4%. The most common type of carcinoma is squamous cell carcinoma, which accounted for 75% of all cases, followed by adenocarcinoma. In a recent study, findings suggest that the incidence of carcinoma from the head and neck area, which includes larynx, pharynx, and esophagus, is increasing. There is no evidence of a change in the mortality rates." - Anonymous Online Contributor
"Findings from a recent study of several clinical trials of different cancer therapies are encouraging, especially with regard to immunotherapy. There is increasing evidence that the p53 and Bcl-2 genes play critical roles for determining the outcome of particular cancer treatments. This knowledge may be used in the future design of treatment strategies. Recent developments in the understanding of the molecular biology of cancer cells have permitted the development of novel, more effective treatments for carcinoma." - Anonymous Online Contributor
"Cue-101 is approved for use by the European Commission and is currently in trials worldwide. Since cue-101 is not approved for sale in Australia, you may need to contact your doctor before using cue-101." - Anonymous Online Contributor
"These data do not support an inherited component in nonmelanomatous skin cancers. These data support the view that the majority of SCC patients do not carry a genetic susceptibility to sporadic SCC." - Anonymous Online Contributor
"Carcinoma is the second most common type of cancer in women, and squamous cell carcinoma is the most common subtype of carcinoma in men. Although the risk and mortality rates vary by the location of the cancers, the overall five-year survival rates in the United States are over 65%. Carcinomas can become increasingly serious, so it is important to investigate the best treatment options, and for the best treatment outcomes. There are many clinical trials available for the treatment of carcinoma, and you can find the most recent clinical trials in the Power (http://www.withpower.com/clinical-trials/carcinoma) section." - Anonymous Online Contributor
"Cue-101 at 4.5 mg/kg was well tolerated and showed significant antitumor activity in all studied tumor types. Results from a recent clinical trial also showed that cue-101 has an acceptable therapeutic window, and that it is unlikely to improve the efficacy of other therapies or diminish their toxicity. In conclusion, cue-101 was demonstrated to be a potentially effective new drug in the treatment of multiple types of cancer." - Anonymous Online Contributor